INT13896

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1980
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 0.77
Pain Relevance 3.50

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Sst) extracellular region (Sst)
Anatomy Link Frequency
neurons 2
somatotrope 2
Sst (Mus musculus)
Pain Link Frequency Relevance Heat
Somatostatin 101 100.00 Very High Very High Very High
opiate 6 99.80 Very High Very High Very High
antagonist 6 98.72 Very High Very High Very High
Calcium channel 2 96.52 Very High Very High Very High
tetrodotoxin 6 96.36 Very High Very High Very High
Serotonin 1 92.08 High High
tolerance 5 90.36 High High
Clonidine 1 88.56 High High
depression 1 86.68 High High
agonist 9 80.40 Quite High
Disease Link Frequency Relevance Heat
Hyperinsulinism 2 100.00 Very High Very High Very High
Impaired Glucose Tolerance 5 90.36 High High
Depression 1 86.68 High High
Insulin Resistance 3 79.72 Quite High
Acromegaly 36 76.80 Quite High
Cancer 24 56.48 Quite High
Alopecia 1 46.60 Quite Low
Constipation 1 46.00 Quite Low
Fatigue 1 45.44 Quite Low
Reprotox - General 1 1 44.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Conversely, neutralization of basal acid secretion with bicarbonate (20-160 nmol/min) caused a decrease in somatostatin secretion in proportion to the decrease in luminal acidity.
Negative_regulation (decrease) of Localization (secretion) of somatostatin associated with somatostatin
1) Confidence 0.59 Published 1988 Journal Gastroenterology Section Abstract Doc Link 2891584 Disease Relevance 0 Pain Relevance 0.42
Similarly, neutralization of the secretagogue-induced increments in acid secretion with bicarbonate or inhibition of the increments with cimetidine abolished the corresponding increments in somatostatin secretion.
Negative_regulation (abolished) of Localization (secretion) of somatostatin associated with somatostatin
2) Confidence 0.43 Published 1988 Journal Gastroenterology Section Abstract Doc Link 2891584 Disease Relevance 0 Pain Relevance 0.41
The selective antagonists 2-amino-5-phosphonovalerate (100 microM) and MK-801 (1 microM) blocked the N-methyl-D-aspartate-evoked release of somatostatin-like immunoreactivity; KCl-evoked release was unaffected.
Negative_regulation (blocked) of Localization (release) of somatostatin associated with antagonist and somatostatin
3) Confidence 0.36 Published 1991 Journal Neuroscience Section Abstract Doc Link 1681466 Disease Relevance 0 Pain Relevance 0.56
The data suggest that : 1) opiates, acting through specific opiate receptors located on LHRH and SRIF neurons, modulate the release of the neurohormones ; 2) the inhibitory effect of opiates could be due to an inhibition of calcium influx through voltage-dependent calcium channels ; 3) this interaction may account for the stimulation of growth hormone and the inhibition of luteinizing hormone observed after systemic administration of opiates ; 4) VIP inhibits SRIF release, by acting on VIP receptors present on MBH SRIF terminals ; the effect is consistent with the stimulation of GH reported after in vivo administration of the peptide.
Negative_regulation (inhibits) of Localization (release) of SRIF in neurons associated with calcium channel, somatostatin and opiate
4) Confidence 0.21 Published 1980 Journal Ann. Endocrinol. (Paris) Section Abstract Doc Link 6113815 Disease Relevance 0 Pain Relevance 1.03
Effects of somatostatin analogs on glucose homeostasis are the resultant of delayed intestinal absorption of carbohydrates, inhibition of insulin release and increased insulin sensitivity via diminished GH secretion.
Negative_regulation (diminished) of Localization (secretion) of somatostatin associated with somatostatin and hyperinsulinism
5) Confidence 0.20 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721386 Disease Relevance 0.69 Pain Relevance 0.17
Taken together, these data suggest that, at supramaximal caerulein concentrations, galanin acts via its receptors to further increase caerulein-stimulated amylase secretion by inhibiting the caerulein-induced release of somatostatin.
Negative_regulation (inhibiting) of Localization (release) of somatostatin associated with somatostatin
6) Confidence 0.12 Published 2009 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 19779018 Disease Relevance 0 Pain Relevance 0.29
It has been proposed that pancreatic somatostatin (SS) tonically inhibits pancreatic glucagon secretion.
Negative_regulation (inhibits) of Localization (secretion) of somatostatin associated with somatostatin
7) Confidence 0.02 Published 1987 Journal Am. J. Physiol. Section Abstract Doc Link 2884887 Disease Relevance 0 Pain Relevance 0.39
This effect may be mediated at the hypothalamic level via reduced 5-HT1A receptor function or at the pituitary level, either by a direct effect on somatotrope cells or via enhanced insulin-like growth factor-1 (IGF-1) or somatostatin (SS) release.
Negative_regulation (reduced) of Localization (release) of SS in somatotrope associated with somatostatin
8) Confidence 0.01 Published 2000 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 11041314 Disease Relevance 0.09 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox